Who is sponsoring NCT01350037?

NCT01350037 is sponsored by Helsinki University Central Hospital.

What condition does NCT01350037 study?

NCT01350037 studies Biliary Tract Diseases, Pancreatic Diseases.

What drugs are being tested in NCT01350037?

Interventions: alfentanil, remifentanil.

What is the status of NCT01350037?

NCT01350037 is currently COMPLETED.

Last reviewed 2012-07-04 · How we verify

Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study

NCT01350037 Phase 4 COMPLETED

Self-administration of propofol and opioid mixture by the patient him- or herself (patient-controlled sedation, PCS) could be successful alternative to the anesthesiologists-managed deep sedation during endoscopic retrograde cholangiopancreatography (ERCP). However, it is not known which opioid would be the most suitable for PCS. The aim of this double-blind study was to compare remifentanil and alfentanil in PCS during ERCP.

Details

Lead sponsor	Helsinki University Central Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	81
Start date	2009-06
Completion	2009-09

Conditions

Biliary Tract Diseases
Pancreatic Diseases

Interventions

alfentanil
remifentanil

Primary outcomes

consumption of propofol and opioid — one day
vital signs — one day
Heart rate (HR), electrocardiogram (ECG), breathing rate, peripheral oxygen saturation (SpO2), end tidal carbon dioxide (EtCO2) constant monitoring. Noninvasive blood pressure (NIBP)measuring at 5 min intervals.

Countries

Finland